Cholinergic suppression of tardive dyskinesia.
D000109:Acetylcholine / Q000502:physiology; D000368:Aged; D001665:Binding Sites; D001921:Brain / Q000378:metabolism; D004298:Dopamine / Q000502:physiology; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology; D010830:Physostigmine / Q000008:administration & dosage / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D009435:Synaptic Transmission; D013997:Time Factors; D014149:Tranquilizing Agents / Q000009:adverse effects
D014149:Tranquilizing Agents; D010830:Physostigmine; D000109:Acetylcholine; D004298:Dopamine